Taken together, these data provide evidence that G2/M blockade by clinical-grade AukB or PLK1 inhibitors may be a viable clinical strategy in ER+ breast cancer cells, including certain CDK4/6i-resistant cancers. Here, CDK4 is linked to breast cancer.